Market Cap 11.52B
Revenue (ttm) 4.38B
Net Income (ttm) -1.04B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 81.65
Profit Margin -23.81%
Debt to Equity Ratio 1.39
Volume 13,881,999
Avg Vol 2,393,952
Day's Range N/A - N/A
Shares Out 181.51M
Stochastic %K 99%
Beta 1.15
Analysts Sell
Price Target $63.42
GoldenTradesCapital
GoldenTradesCapital Jun. 13 at 11:30 AM
🧪 $CTLT – Pharma Supply Rebound? Catalent, a key player in biotech manufacturing, has struggled post-COVID but is showing signs of recovery. $CTLT is speculative but could rebound with pharma demand.
0 · Reply
Samtosemi
Samtosemi May. 10 at 11:06 PM
Yeah you're right I will unblock him. In theory the future best ALS treatment will most likely be a combo therapy. But $BCLI partnered with titan $CTLT has dozens of better alternatives. It is sketchy how therapeutic solutions international inc since 2007 and has not even starting a phased trial for ALS. Chaim is right to not be dragged down with TSI. Nurown which has actually met empirically collected data of stat sig in phase 3 for a genetic ALS about 41% of cases. $TSOI pumpers keep pretending that Allogenic justifies going in blind despite risks of host rejection, disease transfer, & infection. I think most problematic to ALS is allogenic cannot guarantee a consistent quality of cells and Dixon has no registered human trials of Jadicell.
1 · Reply
Max9090
Max9090 Jan. 14 at 7:48 PM
$NVO some 20% yoy growth. Market leader in obesity sector. Their product in high demand. Expanding and buying $CTLT multiple other companies. And the stock is down 50% from its all times high
0 · Reply
NVDAMillionaire
NVDAMillionaire Dec. 26 at 5:41 PM
$CTLT Catalent, Inc. (CTLT): Navigating the Evolving Pharmaceutical Landscape https://beyondspx.com/article/catalent-inc-ctlt-navigating-the-evolving-pharmaceutical-landscape
0 · Reply
DonCorleone77
DonCorleone77 Dec. 23 at 11:13 AM
$LII $CTLT $NVO Lennox to replace Catalent in S&P 500 at open on 12/23 Novo Holdings (NVO) has acquired Catalent (CTLT) in a deal that closed on December 18.
1 · Reply
BellR
BellR Dec. 19 at 4:59 AM
I'm buying more of $JAGX as its price decreases. I have $60,000 available after selling $CTLT
1 · Reply
BellR
BellR Dec. 18 at 6:46 PM
$CTLT sold my holdings and buying $JAGX
0 · Reply
dazedwooderson
dazedwooderson Dec. 18 at 10:40 AM
$CTLT how much is it being bought for?
0 · Reply
StockAutoPro
StockAutoPro Dec. 18 at 5:06 AM
$CTLT: Catalent at $63.48. Speculative buy for $70 as pharma manufacturing pipelines stabilize.
0 · Reply
StockAutoPro
StockAutoPro Dec. 17 at 10:40 PM
$CTLT: Catalent holds at $63.48. A recovery candidate with a target of $75 as supply chain issues improve. Long-term healthcare bet.
0 · Reply
Latest News on CTLT
Catalent Announces New Board Appointments

Feb 20, 2025, 9:00 AM EST - 5 months ago

Catalent Announces New Board Appointments


Novo Holdings completes $16.5 bln takeover of Catalent

Dec 18, 2024, 9:08 AM EST - 7 months ago

Novo Holdings completes $16.5 bln takeover of Catalent

NVO


Novo Holdings Completes Acquisition of Catalent

Dec 18, 2024, 8:57 AM EST - 7 months ago

Novo Holdings Completes Acquisition of Catalent

NVO


Catalent, Inc. Reports First Quarter Fiscal 2025 Results

Nov 5, 2024, 7:00 AM EST - 9 months ago

Catalent, Inc. Reports First Quarter Fiscal 2025 Results


Consumer groups ask FTC to block Novo Holdings-Catalent deal

Oct 17, 2024, 2:03 PM EDT - 9 months ago

Consumer groups ask FTC to block Novo Holdings-Catalent deal

NVO


Catalent to sell New Jersey facility

Oct 14, 2024, 6:40 AM EDT - 9 months ago

Catalent to sell New Jersey facility


Catalent delays filing of annual report

Aug 30, 2024, 5:33 PM EDT - 11 months ago

Catalent delays filing of annual report


Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results

Aug 29, 2024, 7:30 AM EDT - 11 months ago

Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results


Catalent stockholders approve deal with Novo Holdings

May 29, 2024, 9:21 AM EDT - 1 year ago

Catalent stockholders approve deal with Novo Holdings

NVO


Catalent Stockholders Approve Transaction with Novo Holdings

May 29, 2024, 9:07 AM EDT - 1 year ago

Catalent Stockholders Approve Transaction with Novo Holdings


Surely Wines Appoints Brandon Joldersma as New CEO

May 29, 2024, 9:00 AM EDT - 1 year ago

Surely Wines Appoints Brandon Joldersma as New CEO

TMUS


Catalent, Inc. Reports Third Quarter Fiscal 2024 Results

May 8, 2024, 4:15 PM EDT - 1 year ago

Catalent, Inc. Reports Third Quarter Fiscal 2024 Results


International Companies Drive Diabesity Innovation

Mar 29, 2024, 9:59 AM EDT - 1 year ago

International Companies Drive Diabesity Innovation

DXCM LLY NVO STVN


Novo Owner's CEO on Obesity Sales Boom, Catalent Deal

Mar 12, 2024, 6:25 AM EDT - 1 year ago

Novo Owner's CEO on Obesity Sales Boom, Catalent Deal

NVO


Novo Nordisk expects Catalent deal to close later this year

Mar 7, 2024, 10:31 AM EST - 1 year ago

Novo Nordisk expects Catalent deal to close later this year

NVO


Wegovy packing supplier Catalent lays off 300 workers

Feb 14, 2024, 4:44 PM EST - 1 year ago

Wegovy packing supplier Catalent lays off 300 workers


Catalent, Inc. Reports Second Quarter Fiscal 2024 Results

Feb 9, 2024, 7:59 AM EST - 1 year ago

Catalent, Inc. Reports Second Quarter Fiscal 2024 Results


GoldenTradesCapital
GoldenTradesCapital Jun. 13 at 11:30 AM
🧪 $CTLT – Pharma Supply Rebound? Catalent, a key player in biotech manufacturing, has struggled post-COVID but is showing signs of recovery. $CTLT is speculative but could rebound with pharma demand.
0 · Reply
Samtosemi
Samtosemi May. 10 at 11:06 PM
Yeah you're right I will unblock him. In theory the future best ALS treatment will most likely be a combo therapy. But $BCLI partnered with titan $CTLT has dozens of better alternatives. It is sketchy how therapeutic solutions international inc since 2007 and has not even starting a phased trial for ALS. Chaim is right to not be dragged down with TSI. Nurown which has actually met empirically collected data of stat sig in phase 3 for a genetic ALS about 41% of cases. $TSOI pumpers keep pretending that Allogenic justifies going in blind despite risks of host rejection, disease transfer, & infection. I think most problematic to ALS is allogenic cannot guarantee a consistent quality of cells and Dixon has no registered human trials of Jadicell.
1 · Reply
Max9090
Max9090 Jan. 14 at 7:48 PM
$NVO some 20% yoy growth. Market leader in obesity sector. Their product in high demand. Expanding and buying $CTLT multiple other companies. And the stock is down 50% from its all times high
0 · Reply
NVDAMillionaire
NVDAMillionaire Dec. 26 at 5:41 PM
$CTLT Catalent, Inc. (CTLT): Navigating the Evolving Pharmaceutical Landscape https://beyondspx.com/article/catalent-inc-ctlt-navigating-the-evolving-pharmaceutical-landscape
0 · Reply
DonCorleone77
DonCorleone77 Dec. 23 at 11:13 AM
$LII $CTLT $NVO Lennox to replace Catalent in S&P 500 at open on 12/23 Novo Holdings (NVO) has acquired Catalent (CTLT) in a deal that closed on December 18.
1 · Reply
BellR
BellR Dec. 19 at 4:59 AM
I'm buying more of $JAGX as its price decreases. I have $60,000 available after selling $CTLT
1 · Reply
BellR
BellR Dec. 18 at 6:46 PM
$CTLT sold my holdings and buying $JAGX
0 · Reply
dazedwooderson
dazedwooderson Dec. 18 at 10:40 AM
$CTLT how much is it being bought for?
0 · Reply
StockAutoPro
StockAutoPro Dec. 18 at 5:06 AM
$CTLT: Catalent at $63.48. Speculative buy for $70 as pharma manufacturing pipelines stabilize.
0 · Reply
StockAutoPro
StockAutoPro Dec. 17 at 10:40 PM
$CTLT: Catalent holds at $63.48. A recovery candidate with a target of $75 as supply chain issues improve. Long-term healthcare bet.
0 · Reply
DonCorleone77
DonCorleone77 Dec. 15 at 2:20 PM
$NVO $CTLT Novo says Catalent deal regulatory closing conditions fulfilled Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent (CTLT), including expiry of the timing agreement in the U.S., have been fulfilled. The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings. Novo Nordisk now expects the acquisition to be completed in the coming days. Upon completion, the acquisition is expected to impact Novo's financial outlook as issued on November 6, with a low single-digit negative impact on operating profit growth and to negatively impact free cash flow with the $11.7B acquisition price. The company said its ongoing share buyback program of 20B DKK is not impacted. For 2025, the acquisition is expected to have a mid single-digit negative impact on operating profit growth. Novo Nordisk added that its capital allocation priorities focus on internal growth investments, including supply chain expansions, dividends as well as external growth opportunities, including acquiring the three manufacturing sites. Consequently, Novo is not expecting to initiate a share buyback program in 2025.
0 · Reply
thomascresh
thomascresh Dec. 13 at 12:10 AM
$CTLT Is the acquisition a done deal or are we waiting for the FTC/SEC ?
1 · Reply
Schiellerup
Schiellerup Dec. 11 at 8:24 PM
$NVO $CTLT both Novo and Catalent Got a nice volume pump 1:24 PM, coincidence? News comming soon 🔥
2 · Reply
PopPortfolios
PopPortfolios Dec. 11 at 7:13 PM
$CTLT nearly there guys as we predicted it...Final post here.. Could have been so much better deal then Novo.. But anyway good to see +ve return. Good luck all.. On to the next one.
0 · Reply
PenkeTrading
PenkeTrading Dec. 10 at 1:00 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Catalent Inc. Is that bullish or bearish? $CTLT #Catalent #RsiOverbought #NYSE
0 · Reply
Jonita
Jonita Dec. 6 at 7:57 PM
0 · Reply
Jonita
Jonita Dec. 6 at 9:05 AM
$CTLT any news? Shold be the day
1 · Reply
StockConsultant
StockConsultant Dec. 2 at 7:52 PM
$CTLT Catalent stockt, watch for a bull flag breakout at https://stockconsultant.com/?CTLT
0 · Reply